Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LioCyx-M004
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This designation was granted based on the efficacy of LioCyx-M004, an autologous T-cells transfected with mRNA encoding HBsAg, as demonstrated by an improvement in the overall survival in patients with HBsAg-positive HCC relapsed or refractory to prior s...
Product Name : LioCyx-M004
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 23, 2021
Lead Product(s) : LioCyx-M004
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable